EyeMacular Regeneration, Inc.
About EyeMacular Regeneration, Inc.
EyeMacular Regeneration, Inc. (EyeMac Regen) develops specialized surgical instruments and platform technologies for patients progressing to end-stage macular disease, particularly age-related macular degeneration (AMD), who have exhausted existing treatment options. Built on 25 years of research, the company pioneers a novel field called Incisional Choroidal Surgery (ICS). To translate findings into vitreoretinal surgery, it has developed innovative practical tools.
- 🔗 EyeMacular Regeneration 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- 🔗 EyeMacular Regeneration, Inc.
- 🔗 EyeBiotech Ltd. raises $65 million to develop new eye disease therapies | Eye Care Network - Ophthalmology Times
- 🔗 Tissue Regeneration Sciences 2025 Company Profile: Valuation, Funding & Investors | PitchBook
- 🔗 Business Innovation with an “Eye” on Improving Vision | Destination Medical Center
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $2M in a Seed round per PitchBook.
- Holds 11 patents with activity in 4 recent filings.
- Focuses on Incisional Choroidal Surgery for end-stage AMD.
- Operates from St. Paul, Minnesota.
- Website launched at eyemacregen.com describing ICS platform.
Ask StreetZero about EyeMacular Regeneration, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account